Day One Biopharmaceuticals (DAWN) Assets Average: 2022-2025
Historic Assets Average for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $516.4 million.
- Day One Biopharmaceuticals' Assets Average rose 3.15% to $516.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $516.4 million, marking a year-over-year increase of 3.15%. This contributed to the annual value of $479.4 million for FY2024, which is 32.23% up from last year.
- Day One Biopharmaceuticals' Assets Average amounted to $516.4 million in Q3 2025, which was down 1.95% from $526.7 million recorded in Q2 2025.
- Over the past 5 years, Day One Biopharmaceuticals' Assets Average peaked at $591.8 million during Q4 2024, and registered a low of $335.9 million during Q2 2022.
- Its 3-year average for Assets Average is $450.9 million, with a median of $432.5 million in 2023.
- In the last 5 years, Day One Biopharmaceuticals' Assets Average decreased by 6.10% in 2024 and then spiked by 58.98% in 2025.
- Day One Biopharmaceuticals' Assets Average (Quarterly) stood at $365.5 million in 2022, then climbed by 8.11% to $395.1 million in 2023, then surged by 49.78% to $591.8 million in 2024, then climbed by 3.15% to $516.4 million in 2025.
- Its Assets Average was $516.4 million in Q3 2025, compared to $526.7 million in Q2 2025 and $558.6 million in Q1 2025.